ABVC BioPharma Inc
ABVC
Company Profile
Business description
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
Contact
44370 Old Warm Springs Boulevard
FremontCA94538
USAT: +1 510 668-0881
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
19
Stocks News & Analysis
stocks
Chart of the Week: Is CSL finally turning the ship around?
The beaten down healthcare giant remains cheap on turnaround potential.
stocks
ASX top pick remains cheap with narrowing brand focus
Shares remain cheap for ASX winemaker as the company narrows focus on high margin brands.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,816.20 | 50.70 | 0.58% |
| CAC 40 | 8,161.83 | 41.60 | -0.51% |
| DAX 40 | 24,195.31 | 237.75 | -0.97% |
| Dow JONES (US) | 49,918.78 | 953.33 | -1.87% |
| FTSE 100 | 10,254.81 | 27.48 | 0.27% |
| HKSE | 24,279.03 | 128.93 | -0.53% |
| NASDAQ | 25,169.50 | 509.32 | -1.98% |
| Nikkei 225 | 63,868.07 | 311.20 | -0.48% |
| NZX 50 Index | 13,213.70 | 39.95 | -0.30% |
| S&P 500 | 7,266.99 | 119.66 | -1.62% |
| S&P/ASX 200 | 8,618.10 | 54.60 | 0.64% |
| SSE Composite Index | 3,976.71 | 16.51 | -0.41% |